Text extracted via OCR from the original document. May contain errors from the scanning process.
Deutsche Bank
Markets Research
Rating
Buy
North America
United States
Financial
REITs
Company
Medical Properties
Trust
nut:rm
MPW N
MPW UN
NYS
MPW
Long-term hospital opportunity and
attractive relative value: Initiate at Buy
(,Wt: p."1)/
;,. L i.i /RA11
inotilutionni
lip
We believe MPW represents an attractive long-term consolidation play in the
hospital space, given its industry expertise, discounted relative value and
healthy 6% dividend. We think the institutionalization of the hospital real estate
market is poised to accelerate, driven by positive industry trends, increased
comfort with the sale/leaseback model, not-for-profit to for-profit conversions,
and managed care consolidation that could spur additional hospital
consolidation activity. As the only pure play in the hospital space, we believe
MPW stands to benefit the most from these positive trends. With a 15% total
expected return, including a 6% dividend yield, we are initiating with a Buy.
Long-term tailwinds and atti active relative value
Our positive long-term bias is based on 1) the attractive long-term roll-up
opportunity. 2) potential acceleration of acquisition activity, 3) highly stable
and visible cash flows, 4) solid hospital industry trends, and 5) the potential for
a re-rating of the shares as investors become more comfortable with the
hospital sector overall. We fully recognize that the path to realizing MPW's
embedded value will be difficult to measure quarter-to-quarter as acquisitions
are difficult to project and lumpy by nature, but we see the potential for
significant value creation overtime.
Normalization of relative value drives our TP; dividend protects the downside
MPW currently trades at wider-than-historical FFO and AFFO multiple
discounts versus its smaller-cap Healthcare REIT peers. However, we think
there are several reasons why MPW should, at a minimum, trade in line with
historical relative valuations including: 1) prospective earnings upside from
accretive acquisitions; 2) VTR's entry into the hospital space, which should
drive greater price transparency and awareness; and 3) substantial improve-
ments in the scale/diversification of MPW's business versus history. We see
downside protection stemming from MPW's well-covered 6% dividend yield.
Valuation and eisl:s
Our TP of $17 per share equates to a 15% expected return including the 6%
dividend yield. Our TP is based on a 14.3x our 2017 FAD estimate of $1.19. Our
multiple assumption is rich by historical standards, but not relative to the
record low rate environment, and is a 3.5x discount to peers, which is roughly
in line with the five-year average. Key risks include: 1) interest rate sensitivity,
2) above-average government reimbursement risk, 3) above-average tenant
concentration risk, 4) FX and geographic risk given MPW's European exposure,
5) less-robust disclosures vs peers, and 6) healthcare regulatory risks.
Iron/442.1u And iianos
Year End Dec 31
2015A
2016E
2017E
10 FFO
0.28
0.35A
20 FFO
0.29
0.32
30 FFO
0.32
0.30
40 FFO
0.35
0.32
FY FFO (USD)
1.24
1.30
1.32
PlFFO lal
10.5
12.1
11.9
Dividend Yield r/ln
6.7
5.8
5.9
Sown Onesol• au* mown conoinves.
Date
22 July 2016
Initiation of Coverage
Price at 21 Jul 2016 IUSD)
Price Target
52-week range
Research Anal t
VUid
(Pr cenika reiatlyn
15.69
17.00
15.69 - 9.86
V
111' i s1;
tieb:pkOWItt‘w1 /4 ,1
'In
1/14
7/14
ins
7115
ine
V.14.1P•OPHIS 1
SSP 50) WOE( Po boodi
Performance 1%)
Im
3m
12m
Absolute
4.5
23.1
13.0
S&P 500 INDEX
source ClailwA• Sint
4.0
3.9
2.5
Deutsche Bank Securities Inc.
Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should
be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should
consider this report as only a single factor in making their investment decision. DISCLOSURES AND ANALYST
CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 057/04/2016.
CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e)
DB-SDNY-0093200
CONFIDENTIAL
SDNY_GM_00239384
EFTA01389039